Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
about
Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV careCurrent diagnosis and management of peripheral tuberculous lymphadenitisA systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patientsHIV & immune reconstitution inflammatory syndrome (IRIS)Tuberculosis: From an incurable scourge to a curable disease - journey over a millenniumDiagnosis & treatment of tuberculosis in HIV co-infected patients.Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisIncidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort studyScreening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective studyOutcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalenceTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsTreatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, ThailandNeurotuberculosis immune reconstitution inflammatory syndrome in the setting of HIV infection: A case report and review of literature.Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional studyProvider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV statusImmune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy.Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in SenegalLate presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population.Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.TB-IRIS: Proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasoneA non-synonymous polymorphism in IL-23R Gene (rs1884444) is associated with reduced risk to schistosomiasis-associated Immune Reconstitution Inflammatory Syndrome in a Kenyan population.The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort studyAntiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Investigation outcomes of tuberculosis suspects in the health centers of Addis Ababa, Ethiopia.Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort studyAntiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature reviewTiming of antiretroviral therapy after diagnosis of cryptococcal meningitis.Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan childrenRandomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndromeHIV-Associated Tuberculosis.Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART.The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South AfricaManagement of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.
P2860
Q24610933-CDC57203-0A1E-4E95-91B2-F71BCE81BA09Q26829145-6D15BD44-CF2B-4ECE-BE21-0B6FAD99CA80Q26849374-DC846C87-7D7A-4962-B560-78A4AA300245Q26852805-00ACF479-B80D-49F4-BF43-1C6839A81B6DQ26865560-16125F39-B0A6-47FA-B06C-51C8D342A134Q26991633-1F823527-74C8-4AEC-8B90-6587A8DE5DF1Q28088557-220493B2-D5FE-44A9-93F6-8AF58A4829C4Q28476684-64C16D5D-5151-4763-988A-6B33516199B1Q28478173-8ECAEB6C-43D1-4196-A310-4FB22E3373F3Q28479309-6CC8C15F-1A62-4501-B519-E5B7DC35EA52Q28483868-0673B240-358C-4254-B213-256BA2AC8487Q28749315-996D0CD5-1FB6-463E-BB7A-5742601CE195Q30051056-1BCDCDD4-E59E-4431-AB37-75EDC34C9E1AQ31155487-6CDDE86E-706F-49F1-BE78-8FE57C82A4F8Q33284948-0B2803E6-58A8-456C-842C-FE44F115CB24Q33506198-8F6DEDF5-A213-4FDB-8FC4-86015B51747DQ33574709-6E1EB233-B980-46B6-A943-A6B12E3A970CQ33605245-9D8582DC-A6E4-4C1F-B00C-1E8336FEF843Q33616426-B7D5615A-9254-4B73-A787-FFA148E9E17CQ33631762-5BF3F21F-0B38-47EF-944C-DA6FA3C2562EQ33686938-78BF7B22-822D-414E-BFA8-027751AD505BQ33732480-194E3DFB-2669-4DFA-8CBF-E94181A72B29Q33756118-6E4C908F-0D66-4A73-B32F-FA5825476C06Q33758612-7627763E-378A-4178-932F-6CEC6EAEC2D2Q33795967-5BBA92B6-2EFD-4C15-8AEF-AEF633EA7120Q33807615-F42DADF9-D0CE-4B67-8936-66E7AF12AD35Q33883655-495862EB-8DCE-4563-9150-FE8610A5A18BQ33894801-DAE060C5-1CE6-4C71-A223-2250D71301C1Q33920318-6A4BA686-2C9B-4A02-B613-466AA270C14DQ33941296-031BD38B-0FBB-40DC-979C-5E5B6A98F7AAQ34003099-558A456B-66E2-47E8-A119-94FFA95654AFQ34024416-F382C33A-669A-46EB-9714-C2FBF6898482Q34034880-74EF52B3-8E60-4940-B20F-CC012BDA1AA5Q34039981-D8A1EED0-FD3F-4D48-9662-921C05A73A91Q34130659-D49C78DD-A2F0-400B-98C9-2F7A69EF2603Q34143510-DAE3B87B-B480-4269-9F35-3AAC4E59C12CQ34415055-52EE1416-403C-4E1B-97C7-8B2B1A0CC08AQ34423942-3519AEFC-4C07-44CD-A25C-8DED16698432Q34455442-439EF5B9-51D7-49AD-9DEF-8761BB0C5C01Q34463467-DF19D45D-17F3-4E3E-9A10-65356D5530AC
P2860
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Tuberculosis-associated immune ...... tment service in South Africa.
@en
Tuberculosis-associated immune ...... tment service in South Africa.
@nl
type
label
Tuberculosis-associated immune ...... tment service in South Africa.
@en
Tuberculosis-associated immune ...... tment service in South Africa.
@nl
prefLabel
Tuberculosis-associated immune ...... tment service in South Africa.
@en
Tuberculosis-associated immune ...... tment service in South Africa.
@nl
P50
P1433
P1476
Tuberculosis-associated immune ...... tment service in South Africa.
@en
P304
P356
10.1097/QAD.0B013E328011EFAC
P407
P577
2007-01-01T00:00:00Z